Free Newsletter
Vaccines miss their mark in seasonal flu campaign
Each year vaccine makers create a cocktail of antigens designed to stand guard against the various versions of the flu making the rounds in winter. But this year the CDC concludes that most of the influenza B viruses in the U.S. aren't being stopped by the vaccine. Two of the three components in the vaccine aren't aimed the right B targets, it seems. The jab may, though, offer protection against the A versions in circulation.
"Most years, the prediction is very good," Joseph Bresee, an influenza epidemiologist at the CDC, tells the Washington Post. "In 16 of the last 19 years, we have had a well-matched vaccine."
- read the report from the Wall Street Journal
Related Articles:
Universal flu vaccine shows early promise. Report
VaxInnate in a race to produce 'universal' flu vaccine. Report
Flu research points to new delivery technique. Report
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities


SHARE
WITH: